Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
| Horizon | Bear case (−1σ) | Base case | Bull case (+1σ) |
|---|---|---|---|
| 1 Month | 7.38 AUD (-16.0%) | 8.78 AUD | 10.45 AUD (+19.0%) |
| 3 Months | 6.49 AUD (-26.0%) | 8.78 AUD | 11.87 AUD (+35.2%) |
| 6 Months | 5.73 AUD (-34.7%) | 8.78 AUD | 13.45 AUD (+53.2%) |
| 12 Months | 4.80 AUD (-45.3%) | 8.78 AUD | 16.05 AUD (+82.8%) |